Abstract
Serum mass profiling can discern physiological changes associated with specific disease states and their progression. Sera (86 total) from control individuals and patients with stage I nonsmall cell lung cancer or benign small pulmonary nodules were discriminated retrospectively by serum changes discerned by mass profiling. Control individuals were distinguished from patients with Stage I lung cancer or benign nodules with test sensitivities of 89% and 83%. Lung cancer patients versus those with benign nodules were distinguished with 80% sensitivity. This study exhibits progress toward a minimally-invasive aid in early detection of lung cancer and monitoring small pulmonary nodules for malignancy.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Biomarkers, Tumor / blood*
-
Biopsy
-
Carcinoma, Non-Small-Cell Lung / blood
-
Carcinoma, Non-Small-Cell Lung / diagnosis*
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Diagnosis, Differential
-
Early Detection of Cancer
-
Female
-
Humans
-
Lung Neoplasms / blood
-
Lung Neoplasms / diagnosis*
-
Lung Neoplasms / pathology
-
Male
-
Middle Aged
-
Multiple Pulmonary Nodules / blood
-
Multiple Pulmonary Nodules / diagnosis*
-
Multiple Pulmonary Nodules / pathology
-
Neoplasm Staging
-
Predictive Value of Tests
-
Proteomics* / methods
-
Retrospective Studies
-
Solitary Pulmonary Nodule / blood
-
Solitary Pulmonary Nodule / diagnosis*
-
Solitary Pulmonary Nodule / pathology
-
Spectrometry, Mass, Electrospray Ionization
-
Tomography, X-Ray Computed
-
Tumor Burden